← brief for 2026-09-30 · Slowing decline

Cardiovascular safety of orforglipron versus insulin glargine in adults with type 2 diabetes at increased cardiovascular risk (ACHIEVE-4): a phase 3, event-driven, randomised, open-label, non-inferiority, active comparator trial.

Article A Peer reviewed Meta-analysis or large trial

Key takeaways

A large trial tested a new diabetes drug called orforglipron. It compared this drug to insulin in people with type 2 diabetes. The study found the new drug was safe for the heart. This is important because heart health protects the kidneys over time.

Who did this work

Klein KR · Wysham C · Tuttle KR · Davies MJ · Cox D · Chen J · Wu WS · Denning M · Liu R · Ludwig L · Meskimen ER

Source

Article · PubMed, the drug frontier · 2026 Sep 30
https://pubmed.ncbi.nlm.nih.gov/42815506/